Powered by liV Agency

For all enquiries:

Marie Goubran
(514) 220-2743
Nephrologists : 250 $
Nurses, Pharmacists, Dieticians: 75 $
Residents, Students, Others: 20 $

Saturday, December 3, 2022
8 AM to 2:30 PM

Note that the live meeting will be held at Le Westin Montreal
Powered by liV Agency

For all enquiries:

Marie Goubran
8:00 am
Early-Bird Conference (Summary of ASN Highlights)
9:00 am
Opening Remarks: Dr. Michel Vallée, JQH president
Welcoming Remarks by the President of the Canadian Society of Nephrology (CSN): Dr. Claudio Rigatto
9:15 – 10:00 am
The Health of Aboriginal Peoples in the HD Setting
Dr. Murray Vasilevsky conference presented in English
  1. Discuss the prevalence of Aboriginal patients in the hemodialysis setting in Quebec as well as problems that commonly occur
  2. Examine the obstacles Aboriginal patients face
  3. Better understand the Aboriginal patient’s perspective
10:55 – 10:45 am
Antibiotic Therapy in Hemodialysis: Clinical Pearls, Pitfalls and Perils
Jean-François Tessier, pharm.
  1. Define antibiotherapy through an examination of its various applications
  2. Explain how penicillin allergy impacts patient management in the hemodialysis setting
  3. Apply pharmacokinetic and pharmacodynamic concepts to antibiotherapy to better meet the needs of HD patients
10:45 - 11:00 am
Health Break
11:00 – noon
Pierre-Nantel Conference
pruritus in the HD Patient: a real head-scratcher
Dr. Claudio Rigatto conference presented in English
  • To review the epidemiology of this problem: prevalence, risk factors, associated morbidity and impact on patient quality of life
  • To discuss the pathophysiology of pruritus and the evolving knowledge on this topic
  • To provide an update on the treatment options of pruritus with emphasis on the relative efficacy and safety of these treatments
noon - 1:00 pm
1:00 –1:45 pm
The Challenge of Patients with Heart Failure in Hemodialysis
Dr. Michel White
  • Explain the pathophysiology of the HF patient undergoing hemodialysis
  • Organize a response to the specific needs of HF patients in the hemodialysis setting
  • Recognize the grey areas and the challenges in dealing with HF patients receiving HD
1:45 –2:30 pm
What’s new in acute renal replacement therapy?
Dr. Philippe Lachance
  • Explain when to begin and when to stop acute renal replacement therapy
  • Discuss the latest developments in anticoagulation therapy in the acute renal replacement setting
  • Evaluate a new initiative in acute renal replacement therapy
2:30 pm
Closing Remarks: Dr Michel Vallée